Quick Takeaways
- JPMORGAN CHASE & CO filed SCHEDULE 13G for Cartesian Therapeutics, Inc. Common Stock, $0.0001 par value per share (RNAC).
- Disclosed ownership: 6.1%.
- Date of event: 31 Mar 2025.
JPMORGAN CHASE & CO - 31 Mar 2025 SCHEDULE 13G Report for Cartesian Therapeutics, Inc. Common Stock, $0.0001 par value per share (RNAC)
- Filing Manager
- JPMORGAN CHASE & CO
- Reporting Manager
- JPMORGAN CHASE & CO.
- Symbol
- RNAC
- Shares outstanding
- 27,469,443 shares
- Disclosed Ownership
- 1,675,636 shares
- Ownership
- 6.1%
- Form type
- SCHEDULE 13G
- Filing time
- 25 Apr 2025, 14:57:46 UTC
- Date of event
- 31 Mar 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"JPMORGAN CHASE & CO disclosed 6.1% ownership in Cartesian Therapeutics, Inc. Common Stock, $0.0001 par value per share (RNAC) on 31 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 25 Apr 2025, 14:57.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| JPMORGAN CHASE & CO. | 6.1% | 1,675,636 | 1,569,254 | 0 | Rachel Tsvaygoft | Vice President |